drugset / Trial / NCT06100952

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

NCT06100952

Phase 3 Completed 398 enrolled Epion Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Timeline

Start
2023-11-01
Primary completion
2026-02-13
Completion
2026-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Riboflavin Other / unclassified Other
Subject Sodium Iodide Unknown Other

Indications